


# DUBIUS

## #ESCCongress



**Trial Description:** Patients with non-ST-elevation (NSTEMI)-ACS undergoing coronary angiography were randomized to downstream P2Y<sub>12</sub> inhibitor versus upstream P2Y<sub>12</sub> inhibitor.

(p = NS)



### RESULTS

- Primary endpoint, death due to vascular cause, myocardial infarction, stroke, or Bleeding Academic Research Consortium (BARC) 3, 4, 5 bleeding at 30 days, occurred in 2.9% of the downstream group compared with 3.3% of the upstream group (p = nonsignificant)

### CONCLUSIONS

- Among patients with NSTEMI-ACS, downstream P2Y<sub>12</sub> inhibitor administration was not superior to upstream administration

Tarantini G, et al. J Am Coll Cardiol 2020;Aug 21:[Epub]